Xencor, Inc. (NASDAQ:XNCR) Stock Position Increased by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 12.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,567 shares of the biopharmaceutical company’s stock after buying an additional 2,686 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Xencor were worth $542,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of XNCR. GAMMA Investing LLC boosted its position in shares of Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV lifted its stake in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares during the last quarter. Quarry LP boosted its holdings in Xencor by 111.4% during the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 2,108 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 1,337 shares during the last quarter. Finally, Rockefeller Capital Management L.P. bought a new position in shares of Xencor in the third quarter valued at $205,000.

Xencor Price Performance

NASDAQ XNCR opened at $12.95 on Tuesday. The company has a 50 day simple moving average of $16.22 and a 200-day simple moving average of $20.30. Xencor, Inc. has a 52-week low of $12.54 and a 52-week high of $27.24. The firm has a market capitalization of $912.48 million, a price-to-earnings ratio of -4.05 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Equities research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

XNCR has been the topic of a number of recent research reports. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. Wells Fargo & Company cut their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.